Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Pediatric Glaucoma Clinical Trial

Official title:
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Elevated IOP in Pediatric Patients
Glaucoma
Ocular Hypertension
Ocular Hypertension in Pediatric Patients
Pediatric Glaucoma

Clinical Trial Details

NCT number	NCT01652664
Study type	Interventional
Source	Alcon Research
Contact
Status	Completed
Phase	Phase 3
Start date	September 2012
Completion date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05401760` - Combined Phacoaspiration and Angle Surgery Versus Phacoaspiration in Pediatric Cataract	N/A
Recruiting	`NCT03972852` - Establishment of an Anaesthetic Protocol for Examinations for Children With Glaucoma or Suspected Glaucoma
Recruiting	`NCT01494974` - Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma	Phase 4